Antibacterial, Antibiofilm, and Antiviral Farnesol-Containing Nanoparticles Prevent
Anti-Bacterial Agents
/ pharmacology
Antiviral Agents
/ pharmacology
Biofilms
COVID-19
Drug Resistance, Multiple
Farnesol
/ pharmacology
Humans
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Nanoparticles
SARS-CoV-2
Staphylococcal Infections
/ drug therapy
Staphylococcus aureus
SARS-CoV-2
bacterial eradication
biocompatibility
biofilm prevention and elimination
farnesol nanoparticles
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Jul 2022
07 Jul 2022
Historique:
received:
20
06
2022
revised:
02
07
2022
accepted:
05
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Multidrug antimicrobial resistance is a constantly growing health care issue associated with increased mortality and morbidity, and huge financial burden. Bacteria frequently form biofilm communities responsible for numerous persistent infections resistant to conventional antibiotics. Herein, novel nanoparticles (NPs) loaded with the natural bactericide farnesol (FSL NPs) are generated using high-intensity ultrasound. The nanoformulation of farnesol improved its antibacterial properties and demonstrated complete eradication of
Identifiants
pubmed: 35886883
pii: ijms23147527
doi: 10.3390/ijms23147527
pmc: PMC9321328
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antiviral Agents
0
Farnesol
4602-84-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerio de Economía y Competitividad
ID : 869178
Organisme : Ministerio de Economía y Competitividad
ID : PID2019-104111RB-I00
Références
Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
ACS Nano. 2015 Mar 24;9(3):2390-404
pubmed: 25661192
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Viruses. 2012 Jun;4(6):1011-33
pubmed: 22816037
NanoImpact. 2021 Jan;21:100282
pubmed: 35559774
J Antimicrob Chemother. 2003 Nov;52(5):782-9
pubmed: 14563892
ACS Appl Mater Interfaces. 2017 May 3;9(17):15022-15030
pubmed: 28393523
Curr Microbiol. 2011 Oct;63(4):354-9
pubmed: 21800262
Antimicrob Resist Infect Control. 2019 May 16;8:76
pubmed: 31131107
Sci Rep. 2019 Apr 24;9(1):6483
pubmed: 31019274
Nanoscale. 2018 Dec 20;11(1):219-236
pubmed: 30525159
BMC Microbiol. 2015 Feb 18;15:36
pubmed: 25881030
Clin Microbiol Rev. 2013 Apr;26(2):185-230
pubmed: 23554414
Sci Rep. 2020 May 29;10(1):8754
pubmed: 32471975
Lancet. 2001 Jul 14;358(9276):135-8
pubmed: 11463434
ACS Nano. 2016 Apr 26;10(4):4779-89
pubmed: 26998731
ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3314-3323
pubmed: 29313670
Antimicrob Agents Chemother. 2006 Apr;50(4):1463-9
pubmed: 16569866
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Langmuir. 2018 Nov 20;34(46):13935-13945
pubmed: 30351968
Front Microbiol. 2021 Aug 16;12:723498
pubmed: 34484165
Am J Infect Control. 2020 Sep;48(9):1090-1099
pubmed: 32311380
Nat Rev Microbiol. 2009 Sep;7(9):629-41
pubmed: 19680247
Biol Pharm Bull. 2016;39(5):653-6
pubmed: 27150138
J Bone Joint Surg Am. 2009 Nov;91(11):2683-92
pubmed: 19884443
Interdiscip Perspect Infect Dis. 2019 Apr 7;2019:7601847
pubmed: 31080476
Pharmaceuticals (Basel). 2017 Nov 02;10(4):
pubmed: 29099084
Nanomedicine. 2016 Oct;12(7):2061-2069
pubmed: 27288665
J Phys Chem B. 2020 May 21;124(20):4069-4078
pubmed: 32337991
Heliyon. 2018 Dec 28;4(12):e01067
pubmed: 30619958
Molecules. 2018 Oct 31;23(11):
pubmed: 30384444
Medicines (Basel). 2017 Aug 08;4(3):
pubmed: 28930272
ACS Appl Mater Interfaces. 2020 Aug 12;12(32):35918-35927
pubmed: 32672937
J Mol Biol. 2021 Aug 6;433(16):166968
pubmed: 33798529